Related Experiment Videos
Alterations in lipoprotein composition in peritoneal dialysis patients
James B Moberly1, Per-Ola Attman, Ola Samuelsson
1Renal Division, Baxter Healthcare Corporation, McGaw Park, Illinois 60085-6730, USA. moberlj@baxter.com
Summary
Patients with end-stage renal disease on dialysis exhibit dyslipidemia. Peritoneal dialysis patients show elevated ApoB in LDL, distinguishing them from hemodialysis patients and highlighting cardiovascular risks.
Area of Science:
- Nephrology and Clinical Biochemistry
- Lipid Metabolism and Cardiovascular Risk Assessment
Background:
- Dyslipidemia is a prevalent comorbidity in patients with end-stage renal disease (ESRD) undergoing renal replacement therapy.
- Understanding specific lipoprotein abnormalities in peritoneal dialysis (PD) patients is crucial for managing associated cardiovascular risks.
Purpose of the Study:
- To characterize and compare the lipid and apolipoprotein (Apo) composition of very low density (VLDL), intermediate density (IDL), low density (LDL), and high density lipoproteins (HDL).
- To identify distinct lipoprotein alterations in PD patients compared to hemodialysis (HD) patients and healthy controls.
Main Methods:
- Fasting plasma samples were collected from 15 non-diabetic PD patients, 15 non-diabetic HD patients, and 16 healthy controls.
- Lipoproteins were isolated using preparative ultracentrifugation.
- Lipid and apolipoprotein concentrations were quantified via gas chromatography and electroimmunoassay, respectively.
Main Results:
- Both PD and HD patients displayed altered lipoprotein composition across all four density classes.
- Elevated ApoCIII was observed in VLDL, IDL, and LDL of both PD and HD patients.
- PD patients showed a significant elevation of ApoB in LDL, a key difference compared to HD patients.
Conclusions:
- Increased lipid and apolipoprotein mass in IDL and enrichment of ApoCIII in VLDL, IDL, and LDL are common in ESRD patients on dialysis.
- Elevated ApoB in LDL is the predominant lipoprotein alteration distinguishing PD patients from HD patients.
- Further research into these lipoprotein changes in PD patients is essential for understanding dyslipidemia and guiding therapeutic strategies to mitigate cardiovascular risk.